Effectiveness, safety and impact of HPV prophylactic vaccine

• OC 13-01 • Brazilian public HPV vaccination program: first two years of experience See abstract > L. Leandro Resende • OC 13-02 • Effectiveness of the quadrivalent human papillomavirus vaccine against anogenital warts in Manitoba, Canada: a population-based study See abstract > K. Karla Willows • OC 13-03 • Effectiveness, immunogenicity, and safety of Gardasil ™ in pre-adolescents and adolescents – 10 years of follow-up See abstract > O-E. Ole-Erik Iversen • OC 13-04 • Impact and effectiveness of the quadrivalent human papillomavirus vaccine: ten years of real world experience See abstract > S. Suzanne Garland • OC 13-05 • Cost-effectiveness evaluation of the quadrivalent HPV vaccine in South Korea using a dynamic transmission model See abstract > M. Matthew Pillsbury • OC 13-06 • Public health benefits of routine human papillomavirus vaccination for adults in the Netherlands: a mathematical modeling study See abstract > S. S. Matthijsse • OC 13-07 • Public health impact of a nine-valent HPV vaccination program for females in Hungary using a dynamic transmission model See abstract > L. L. Nagy • OC 13-08 • WOLVES-STUDY – IMPACT OF HPV VACCINATION IN WOLFSBURG (GERMANY) See abstract > S. Sarah Strehlke • OC 13-09 • Public health impact of a nine-valent HPV vaccination program for females and males in Hungary using a HPV transmission dynamic model See abstract > J. Jonas Kalmar • OC 13-10 • Long-term safety of the HPV-16/18 AS04-adjvanted vaccine See abstract > W. Wiebren Tjalma • OC 13-11 • Safety and immunogenicity of the HPV -16/18 AS04-adjuvanted vaccine in adolescents : final analysis of a large community-randomized trial in Finland See abstract > D. Dan Bi • OC 13-12 • Safety profile of the 9-valent HPV vaccine: a combined analysis of seven phase III clinical studies See abstract > E. Edson Moreira • OC 13-13 • End of study efficacy for vulvovaginal disease of a novel 9-valent HPV L1 virus-like particle vaccine in 16-26 year old women See abstract > E. Elmar Joura • OC 13-14 • Estimating the cost-effectiveness of a universal vaccination programme with a nonavalent HPV vaccine in Italy See abstract > C. Chiara De Waure • OC 13-15 • Human papillomavirus (HPV) vaccine coverage achievements in thirty low and middle-income countries between 2007-2015 See abstract > K. Katherine Gallagher • OC 13-16 • HPV Vaccination Coverage at 2 years of Initiating the National Vaccination Programe for Chilean Girls See abstract > A. Andrea Schilling • OC 13-17 • Cost-effectiveness evaluation of the quadrivalent HPV vaccination program for females age 11-12 years in Thailand See abstract > N. Nipon Khemapech